NORD's Role in Advancing NDDs Research (G79625)

Target Name: NDNF

NCBI ID: G79625

NDNF

NORD's Role in Advancing NDDs Research

Neurodegenerative diseases (NDDs) are a group of progressive conditions that affect the brain and nervous system. These conditions include Alzheimer's disease, Parkinson's disease, Huntington's disease, and other forms of dementia. Despite advances in treatment, the majority of NDDs continue to be irreversible and are often associated with significant quality of life loss.

One potential drug target for NDDs is NORD (Neurodegenerative Disease Research Fund), a nonprofit organization dedicated to funding research into the causes and treatments of NDDs. NORD has awarded over $45 million in grants to more than 1,700 research projects in the past 15 years and has been instrumental in the development of new treatments for NDDs.

One of the key areas of focus for NORD is the development of therapies that can slow the progression of NDDs. This is an important goal, as the earlier a disease is diagnosed and treated, the more effective the treatment is likely to be. NORD has supported research in a wide range of areas, including neuroimaging, neurotransmitter biology, and neurodegeneration.

One of the key approaches that NORD has taken to support research in NDDs is the establishment of theNDDF (National Institute on Degenerative Diseases). This Institute, which is part of the National Institutes of Health (NIH), is dedicated to funding and supporting research inNDDs and related fields. TheNDDF has awarded over $1.5 billion in grants and contracts to more than 1,400 research projects in the past 15 years.

Another important aspect of NORD's work is its focus on collaboration. NORD has established partnerships with a wide range of organizations and institutions, including academic medical centers, hospitals, and government agencies. These partnerships have facilitated collaboration among researchers and have helped to accelerate the development of new treatments for NDDs.

One of the key benefits of NORD is its commitment to transparency and accountability. NORD regularly releases information about the grants it has awarded and the progress of the research projects it has supported. This transparency has helped to build trust among the research community and has helped to ensure that the funds provided by NORD are being used effectively.

Overall, NORD is a valuable resource for researchers working on NDDs. Its support for research has helped to accelerate the development of new treatments for these conditions and has contributed to the progress that has been made in our understanding of these debilitating diseases. As the NDDF continues to fund research in NDDs, it is likely to play an important role in the search for new treatments and in the care and treatment of people with these conditions.

Protein Name: Neuron Derived Neurotrophic Factor

Functions: Secretory protein that plays a role in various cellular processes (PubMed:20969804, PubMed:24706764, PubMed:31883645). Acts as a chemorepellent acting on gonadotropin-releasing hormone (GnRH) expressing neurons regulating their migration to the hypothalamus (PubMed:31883645). Also promotes neuron migration, growth and survival as well as neurite outgrowth and is involved in the development of the olfactory system (PubMed:20969804, PubMed:31883645). May also act through the regulation of growth factors activity and downstream signaling (PubMed:31883645). Also regulates extracellular matrix assembly and cell adhesiveness (By similarity). Promotes endothelial cell survival, vessel formation and plays an important role in the process of revascularization through NOS3-dependent mechanisms (PubMed:24706764)

The "NDNF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDNF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets